FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571567455> ?p ?o ?g. }

• W2571567455 abstract "Abstract Haploidentical stem cell transplantation (SCT) can be used in relapsed haematological malignancies for patients lacking a matched sibling or unrelated donor. Major barriers of this strategy are the poor immune reconstitution and the high risk of relapse. Here, we report results of a phase I–II trial evaluating early add-backs of CD8-depleted donor lymphocytes (DLIs) (from 1x10^4 up to 1x10^5 cells/kg starting at day+45 up to day +105 at monthly intervals) after a reduced intensity conditioning (RIC) regimen [thiotepa (10 mg/kg), fludarabine (120 mg/sqm), cyclophosphamide (60 mg/kg) and TBI (2 Gy)]. Ex-vivo and in-vivo TCD were carried out by CD34+ cell selection using the CliniMACS device and alemtuzumab (15mg/m2, day-2), respectively. Twenty-one patients [n= 10 NHL (n=5 CLL, n=5 high-grade NHL), n=7 HL, n=1 MM, n=1 ALL, n=2 AML] were transplanted with advanced disease: 16 (76%) failed a previous autograft and 13 (62%) had refractory disease. A median of 10.4x10^6/Kg CD34+, 1x10^4/kg CD3+, 10x10^4/kg CD19+, 0.9 x10^4/kg NK+ were infused. All patients engrafted with full donor chimerism from day +90. At a median follow-up of 12 months (range, 4–41 months), 12 of 21 pts are alive (7 CR, 2 PR and 3 PD) and 9 died [n=3 infection with GVHD (+610, +187, +253), n=6 disease]. The estimated 2-year overall survival was 49%: pts transplanted in remission had better outcome (83% versus 31%, p=0.13). The estimated 2-year cumulative incidence of TRM and relapse were 27% and 58%, respectively. CMV reactivation and hospital readmissions for opportunistic infections occurred in 76% and 57% of patients, respectively. For CD8 depletion of donor leukaphereses, a new depletion protocol using clinical grade CD8 microbeads (Miltenyi) was applied. This procedure is efficient to reduce the content of CD8 T cells by 3 logs while the median cell recovery of CD3+, CD4+, CD56+/CD3+, CD 20+ was 60%, 86%, 54%, 72%, respectively. Before DLIs, only 2 of 21 patients (10%) developed acute GVHD (no grade III–IV). A total of 36 CD8-depleted DLIs were administered to 17 pts without any acute toxicity. Following DLIs, 6 pts (35%) developed acute GVHD (grade II) and 5 (30%) chronic GVHD (n=2 limited, n=3 extensive). Overall, the incidence of acute GVHD is higher (50% vs 22%, p=0.33) in pts receving larger numbers of donor cells (10–15x10^4/kg versus 3–5x10^4/kg CD8-depleted DLIs). The median values of CD4+/uL, CD8+/uL and NK+ were 100, 280 and 680 at 4 months and 220, 200, 500 at 6 months after SCT in patients receiving CD8-depleted DLIs. Measurable TREC/ucg DNA (mean value 316; mean value donors 3740) and polyclonal T cell repertoire, evaluated by spectratyping, were observed at 9 months in patients younger than 40 years and/or without GVHD. Our results suggest that: haploidentical SCT with RIC regimen provides high engraftment rate T-cell addback allows the achievement of more than 100/uL CD4+ at 4 months after SCT in the majority of patients Survival rate is promising in patients who had transplantation in remission suggesting that this strategy should be evaluated earlier in high risk haematological diseases." @default.
• W2571567455 created "2017-01-26" @default.
• W2571567455 creator A5012221586 @default.
• W2571567455 creator A5012911614 @default.
• W2571567455 creator A5025214732 @default.
• W2571567455 creator A5028619240 @default.
• W2571567455 creator A5028678248 @default.
• W2571567455 creator A5039504007 @default.
• W2571567455 creator A5044096591 @default.
• W2571567455 creator A5048746808 @default.
• W2571567455 creator A5053560614 @default.
• W2571567455 creator A5061751736 @default.
• W2571567455 creator A5065659848 @default.
• W2571567455 creator A5068769311 @default.
• W2571567455 creator A5090133153 @default.
• W2571567455 date "2006-11-16" @default.
• W2571567455 modified "2023-10-16" @default.
• W2571567455 title "CD8-Depleted Donor Lymphocyte Infusions Can Boost Immune Reconstitution after Haploidentical Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen." @default.
• W2571567455 doi "https://doi.org/10.1182/blood.v108.11.3138.3138" @default.
• W2571567455 hasPublicationYear "2006" @default.
• W2571567455 type Work @default.
• W2571567455 sameAs 2571567455 @default.
• W2571567455 citedByCount "2" @default.
• W2571567455 crossrefType "journal-article" @default.
• W2571567455 hasAuthorship W2571567455A5012221586 @default.
• W2571567455 hasAuthorship W2571567455A5012911614 @default.
• W2571567455 hasAuthorship W2571567455A5025214732 @default.
• W2571567455 hasAuthorship W2571567455A5028619240 @default.
• W2571567455 hasAuthorship W2571567455A5028678248 @default.
• W2571567455 hasAuthorship W2571567455A5039504007 @default.
• W2571567455 hasAuthorship W2571567455A5044096591 @default.
• W2571567455 hasAuthorship W2571567455A5048746808 @default.
• W2571567455 hasAuthorship W2571567455A5053560614 @default.
• W2571567455 hasAuthorship W2571567455A5061751736 @default.
• W2571567455 hasAuthorship W2571567455A5065659848 @default.
• W2571567455 hasAuthorship W2571567455A5068769311 @default.
• W2571567455 hasAuthorship W2571567455A5090133153 @default.
• W2571567455 hasConcept C126322002 @default.
• W2571567455 hasConcept C141071460 @default.
• W2571567455 hasConcept C167672396 @default.
• W2571567455 hasConcept C203014093 @default.
• W2571567455 hasConcept C2776694085 @default.
• W2571567455 hasConcept C2776755627 @default.
• W2571567455 hasConcept C2778880498 @default.
• W2571567455 hasConcept C2779015954 @default.
• W2571567455 hasConcept C2779263901 @default.
• W2571567455 hasConcept C2779968505 @default.
• W2571567455 hasConcept C2779972918 @default.
• W2571567455 hasConcept C2781413609 @default.
• W2571567455 hasConcept C2911091166 @default.
• W2571567455 hasConcept C71924100 @default.
• W2571567455 hasConcept C8891405 @default.
• W2571567455 hasConcept C90924648 @default.
• W2571567455 hasConceptScore W2571567455C126322002 @default.
• W2571567455 hasConceptScore W2571567455C141071460 @default.
• W2571567455 hasConceptScore W2571567455C167672396 @default.
• W2571567455 hasConceptScore W2571567455C203014093 @default.
• W2571567455 hasConceptScore W2571567455C2776694085 @default.
• W2571567455 hasConceptScore W2571567455C2776755627 @default.
• W2571567455 hasConceptScore W2571567455C2778880498 @default.
• W2571567455 hasConceptScore W2571567455C2779015954 @default.
• W2571567455 hasConceptScore W2571567455C2779263901 @default.
• W2571567455 hasConceptScore W2571567455C2779968505 @default.
• W2571567455 hasConceptScore W2571567455C2779972918 @default.
• W2571567455 hasConceptScore W2571567455C2781413609 @default.
• W2571567455 hasConceptScore W2571567455C2911091166 @default.
• W2571567455 hasConceptScore W2571567455C71924100 @default.
• W2571567455 hasConceptScore W2571567455C8891405 @default.
• W2571567455 hasConceptScore W2571567455C90924648 @default.
• W2571567455 hasLocation W25715674551 @default.
• W2571567455 hasOpenAccess W2571567455 @default.
• W2571567455 hasPrimaryLocation W25715674551 @default.
• W2571567455 hasRelatedWork W168805849 @default.
• W2571567455 hasRelatedWork W2028308909 @default.
• W2571567455 hasRelatedWork W2058090754 @default.
• W2571567455 hasRelatedWork W2252295961 @default.
• W2571567455 hasRelatedWork W2556447710 @default.
• W2571567455 hasRelatedWork W2615902868 @default.
• W2571567455 hasRelatedWork W2620956092 @default.
• W2571567455 hasRelatedWork W2754125581 @default.
• W2571567455 hasRelatedWork W2969232618 @default.
• W2571567455 hasRelatedWork W2979354104 @default.
• W2571567455 isParatext "false" @default.
• W2571567455 isRetracted "false" @default.
• W2571567455 magId "2571567455" @default.
• W2571567455 workType "article" @default.